Merrimack Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-441-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$144.27 million
Profitability
Miscellaneous
Employees27
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions
What is Merrimack Pharmaceuticals' stock symbol?
Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."
When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?
Merrimack Pharmaceuticals shares reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
How were Merrimack Pharmaceuticals' earnings last quarter?
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced its quarterly earnings data on Wednesday, July, 17th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter. View Merrimack Pharmaceuticals' Earnings History.
When is Merrimack Pharmaceuticals' next earnings date?
What price target have analysts set for MACK?
2 brokers have issued 12-month price objectives for Merrimack Pharmaceuticals' shares. Their predictions range from $4.00 to $4.00. On average, they expect Merrimack Pharmaceuticals' stock price to reach $4.00 in the next year. This suggests that the stock has a possible downside of 40.7%. View Analyst Price Targets for Merrimack Pharmaceuticals.
What is the consensus analysts' recommendation for Merrimack Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merrimack Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Merrimack Pharmaceuticals.
Has Merrimack Pharmaceuticals been receiving favorable news coverage?
News stories about MACK stock have been trending positive on Sunday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Merrimack Pharmaceuticals earned a news impact score of 2.5 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the next few days. View News Stories for Merrimack Pharmaceuticals.
Who are some of Merrimack Pharmaceuticals' key competitors?
Some companies that are related to Merrimack Pharmaceuticals include XBiotech (XBIT), AMAG Pharmaceuticals (AMAG), Akorn (AKRX), Kadmon (KDMN), Protagonist Therapeutics (PTGX), Albireo Pharma (ALBO), Mirum Pharmaceuticals (MIRM), Theratechnologies (THERF), BIOFRONTERA AG/ADR (BFRA), Clovis Oncology (CLVS), Rigel Pharmaceuticals (RIGL), ProQR Therapeutics (PRQR), Assembly Biosciences (ASMB), Arcus Biosciences (RCUS) and Xeris Pharmaceuticals (XERS).
What other stocks do shareholders of Merrimack Pharmaceuticals own?
Who are Merrimack Pharmaceuticals' key executives?
Merrimack Pharmaceuticals' management team includes the folowing people:
- Dr. Richard Peters, Pres, CEO & Director (Age 56)
- Ms. Jean M. Franchi, CFO & Treasurer (Age 53)
- Mr. Jeffrey A. Munsie, Gen. Counsel, Head of Corp. Operations & Sec. (Age 42)
- Dr. Daryl C. Drummond Ph.D., Head of Research (Age 50)
- Dr. Sergio L. Santillana, Chief Medical Officer (Age 56)
Who are Merrimack Pharmaceuticals' major shareholders?
Merrimack Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Nuveen Asset Management LLC (3.55%), Vanguard Group Inc. (2.82%), BlackRock Inc. (1.88%), Wittenberg Investment Management Inc. (1.44%), Connor Clark & Lunn Investment Management Ltd. (1.17%) and Invesco Ltd. (0.42%). Company insiders that own Merrimack Pharmaceuticals stock include Fund Lp 22Nw, Jason Aryeh, Jfl Capital Management, Llc, Lp 22Nw and Ulrik B Nielsen. View Institutional Ownership Trends for Merrimack Pharmaceuticals.
Which major investors are selling Merrimack Pharmaceuticals stock?
Which major investors are buying Merrimack Pharmaceuticals stock?
MACK stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Vanguard Group Inc., Citadel Advisors LLC and Jacobs Levy Equity Management Inc.. Company insiders that have bought Merrimack Pharmaceuticals stock in the last two years include Fund Lp 22Nw, Jason Aryeh, Jfl Capital Management, Llc and Lp 22Nw. View Insider Buying and Selling for Merrimack Pharmaceuticals.
How do I buy shares of Merrimack Pharmaceuticals?
Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Merrimack Pharmaceuticals' stock price today?
One share of MACK stock can currently be purchased for approximately $6.74.
How big of a company is Merrimack Pharmaceuticals?
What is Merrimack Pharmaceuticals' official website?
How can I contact Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals' mailing address is ONE KENDALL SQUARE SUITE B7201, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]
MarketBeat Community Rating for Merrimack Pharmaceuticals (NASDAQ MACK)
MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe MACK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MACK will underperform the S&P 500 over the long term. You may vote once every thirty days.
